表观遗传学在肺动脉高压中的新兴作用：临床试验的重要途径（2015年格罗弗会议系列）
The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series).
作者信息
Huston Jessica H, Ryan John J
机构信息
Department of Medicine, Salt Lake City Veterans Affairs Medical Center, Salt Lake City, Utah, USA.
Division of Cardiovascular Medicine, Department of Medicine, University of Utah, Salt Lake City, Utah, USA.
出版信息
Pulm Circ. 2016 Sep;6(3):274-84. doi: 10.1086/687765.
Abstract
Epigenetics is an emerging field of research and clinical trials in cancer therapy that also has applications for pulmonary arterial hypertension (PAH), as there is evidence that epigenetic control of gene expression plays a significant role in PAH. The three types of epigenetic modification include DNA methylation, histone modification, and RNA interference. All three have been shown to be involved in the development of PAH. Currently, the enzymes that perform these modifications are the primary targets of neoplastic therapy. These targets are starting to be explored for therapies in PAH, mostly in animal models. In this review we summarize the basics of each type of epigenetic modification and the known sites and molecules involved in PAH, as well as current targets and prospects for clinical trials.
摘要
表观遗传学是癌症治疗研究和临床试验中一个新兴的领域，在肺动脉高压（PAH）中也有应用，因为有证据表明基因表达的表观遗传控制在PAH中起着重要作用。三种表观遗传修饰类型包括DNA甲基化、组蛋白修饰和RNA干扰。所有这三种修饰都已被证明与PAH的发展有关。目前，进行这些修饰的酶是肿瘤治疗的主要靶点。这些靶点正开始在PAH治疗中进行探索，主要是在动物模型中。在这篇综述中，我们总结了每种表观遗传修饰类型的基础知识、PAH中涉及的已知位点和分子，以及当前的靶点和临床试验前景。
相似文献
1
The emerging role of epigenetics in pulmonary arterial hypertension: an important avenue for clinical trials (2015 Grover Conference Series).表观遗传学在肺动脉高压中的新兴作用：临床试验的重要途径（2015年格罗弗会议系列）
Pulm Circ. 2016 Sep;6(3):274-84. doi: 10.1086/687765.
2
Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.表观遗传调控作为肺动脉高压的一种治疗方法。
Exp Mol Med. 2015 Jul 31;47(7):e175. doi: 10.1038/emm.2015.45.
3
Epigenetic Mechanisms as Emerging Therapeutic Targets and Microfluidic Chips Application in Pulmonary Arterial Hypertension.表观遗传机制作为新兴治疗靶点及微流控芯片在肺动脉高压中的应用
Biomedicines. 2022 Jan 13;10(1):170. doi: 10.3390/biomedicines10010170.
4
Epigenetic mechanisms of pulmonary hypertension.肺动脉高压的表观遗传机制。
Pulm Circ. 2011 Jul-Sep;1(3):347-56. doi: 10.4103/2045-8932.87300.
5
Integrating epigenetics and metabolomics to advance treatments for pulmonary arterial hypertension.整合表观遗传学和代谢组学以推进肺动脉高压的治疗
Biochem Pharmacol. 2022 Oct;204:115245. doi: 10.1016/j.bcp.2022.115245. Epub 2022 Sep 10.
6
Epigenetic regulation of pulmonary arterial hypertension.肺高血压的表观遗传调控。
Hypertens Res. 2011 Sep;34(9):981-6. doi: 10.1038/hr.2011.79. Epub 2011 Jun 16.
7
Epigenetic modifications: basic mechanisms and role in cardiovascular disease (2013 Grover Conference series).表观遗传学修饰：基本机制及其在心血管疾病中的作用（2013 年 Grover 会议系列）。
Pulm Circ. 2014 Jun;4(2):169-74. doi: 10.1086/675979.
8
Exploring the pathogenesis of pulmonary vascular disease.探索肺血管疾病的发病机制。
Front Med (Lausanne). 2024 Jul 10;11:1402639. doi: 10.3389/fmed.2024.1402639. eCollection 2024.
9
Role of histone lactylation interference RNA mA modification and immune microenvironment homeostasis in pulmonary arterial hypertension.组蛋白乳酰化干扰RNA mA修饰及免疫微环境稳态在肺动脉高压中的作用
Front Cell Dev Biol. 2023 Sep 12;11:1268646. doi: 10.3389/fcell.2023.1268646. eCollection 2023.
10
Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension.肺动脉高压潜在表观遗传机制的见解
Braz J Med Biol Res. 2018 Oct 18;51(12):e7437. doi: 10.1590/1414-431X20187437.
引用本文的文献
1
Vitamin C deficiency can lead to pulmonary hypertension: a systematic review of case reports.维生素 C 缺乏可导致肺动脉高压：病例报告的系统评价。
BMC Pulm Med. 2024 Mar 19;24(1):140. doi: 10.1186/s12890-024-02941-x.
2
Transgenerational inheritance of promoter methylation changes in extrauterine growth restriction-induced pulmonary arterial pressure disorders.宫外生长受限诱导的肺动脉压力紊乱中启动子甲基化变化的跨代遗传
Ann Transl Med. 2021 Oct;9(20):1551. doi: 10.21037/atm-21-4715.
3
The Short-Chain Fatty Acid Butyrate Attenuates Pulmonary Vascular Remodeling and Inflammation in Hypoxia-Induced Pulmonary Hypertension.短链脂肪酸丁酸盐可减轻低氧诱导的肺动脉高压中的肺血管重构和炎症。
Int J Mol Sci. 2021 Sep 14;22(18):9916. doi: 10.3390/ijms22189916.
4
Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial Hypertension.肺动脉高压右心室功能障碍的治疗靶点
JACC Basic Transl Sci. 2020 Dec 28;5(12):1244-1260. doi: 10.1016/j.jacbts.2020.07.011. eCollection 2020 Dec.
5
Epigenetic Inactivation of the Tumor Suppressor Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis.肿瘤抑制因子的表观遗传失活在肺腺癌中频繁发生，其沉默与预后不良相关。
Cancers (Basel). 2020 Nov 26;12(12):3528. doi: 10.3390/cancers12123528.
6
Disease severity-related alterations of cardiac microRNAs in experimental pulmonary hypertension.实验性肺动脉高压中心脏 microRNAs 与疾病严重程度相关的改变。
J Cell Mol Med. 2020 Jun;24(12):6943-6951. doi: 10.1111/jcmm.15352. Epub 2020 May 12.
7
Long noncoding RNAs: emerging roles in pulmonary hypertension.长链非编码RNA：在肺动脉高压中的新作用
Heart Fail Rev. 2020 Sep;25(5):795-815. doi: 10.1007/s10741-019-09866-2.
8
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase.miR-410 通过调控烟酰胺磷酸核糖转移酶抑制肺血管重构。
Sci Rep. 2019 Jul 9;9(1):9949. doi: 10.1038/s41598-019-46352-z.
9
Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension.肺动脉高压潜在表观遗传机制的见解
Braz J Med Biol Res. 2018 Oct 18;51(12):e7437. doi: 10.1590/1414-431X20187437.
10
Evolving systems biology approaches to understanding non-coding RNAs in pulmonary hypertension.不断发展的系统生物学方法，旨在理解肺动脉高压中的非编码 RNA。
J Physiol. 2019 Feb;597(4):1199-1208. doi: 10.1113/JP275855. Epub 2018 Sep 2.
本文引用的文献
1
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association.整合电子健康记录数据与基因组学用于心血管研究：美国心脏协会的科学咨询意见
Circ Cardiovasc Genet. 2016 Apr;9(2):193-202. doi: 10.1161/HCG.0000000000000029. Epub 2016 Mar 14.
2
MicroRNA-103/107 is involved in hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by targeting HIF-1β.微小RNA-103/107通过靶向低氧诱导因子-1β参与低氧诱导的肺动脉平滑肌细胞增殖。
Life Sci. 2016 Feb 15;147:117-24. doi: 10.1016/j.lfs.2016.01.043. Epub 2016 Jan 29.
3
DNA methylation pathways and their crosstalk with histone methylation.DNA甲基化途径及其与组蛋白甲基化的相互作用。
Nat Rev Mol Cell Biol. 2015 Sep;16(9):519-32. doi: 10.1038/nrm4043.
4
Bromodomain-Containing Protein 4: The Epigenetic Origin of Pulmonary Arterial Hypertension.溴结构域蛋白 4：肺动脉高压的表观遗传起源。
Circ Res. 2015 Aug 28;117(6):525-35. doi: 10.1161/CIRCRESAHA.115.307004. Epub 2015 Jul 29.
5
Downregulation of MicroRNA-126 Contributes to the Failing Right Ventricle in Pulmonary Arterial Hypertension.miR-126 的下调导致肺动脉高压右心衰竭。
Circulation. 2015 Sep 8;132(10):932-43. doi: 10.1161/CIRCULATIONAHA.115.016382. Epub 2015 Jul 10.
6
Emerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series).组蛋白去乙酰化酶在肺动脉高压和右心室重构中的新作用（2013 年 Grover 会议系列）。
Pulm Circ. 2015 Mar;5(1):63-72. doi: 10.1086/679700.
7
Modulation of miRNAs in Pulmonary Hypertension.肺动脉高压中微小RNA的调控
Int J Hypertens. 2015;2015:169069. doi: 10.1155/2015/169069. Epub 2015 Mar 11.
8
Right ventricular adaptation and failure in pulmonary arterial hypertension.肺动脉高压时右心室的适应与衰竭
Can J Cardiol. 2015 Apr;31(4):391-406. doi: 10.1016/j.cjca.2015.01.023. Epub 2015 Jan 29.
9
Loss of microRNA-17∼92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5.平滑肌细胞中微小RNA-17∼92的缺失通过诱导PDZ和LIM结构域5减轻实验性肺动脉高压。
Am J Respir Crit Care Med. 2015 Mar 15;191(6):678-92. doi: 10.1164/rccm.201405-0941OC.
10
Building the case for novel clinical trials in pulmonary arterial hypertension.为肺动脉高压新型临床试验提供依据。
Circ Cardiovasc Qual Outcomes. 2015 Jan;8(1):114-23. doi: 10.1161/CIRCOUTCOMES.114.001319.
Zotero 插件